Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults
The Journal of Clinical Pharmacology · 2026-05 · 66 (5)
DOI: 10.1002/jcph.70203 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 15.05.2026. Verfasst von Emma Ilsley und 9 weiteren Autor:innen. Beteiligte Einrichtung: GSK, London, UK. Hauptthemen laut MEDLINE: Antitubercular Agents. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, Innovative Medicines Initiative 2 Joint Undertaking (JU), GlaxoSmithKline foundation.
Abstract (Originalsprache)
This first‐in‐human study (ClinicalTrials.gov identifier: NCT04472897) evaluated the safety, tolerability, pharmacokinetics, and food effect of single ascending and repeat oral doses of GSK2556286 (GSK286), a novel antitubercular drug candidate with efficacy in animal models of tuberculosis. In part A, 56 participants received single GSK286 doses (25–1000 mg; 10 cohorts) and 19 participants received a placebo. In part B, GSK286 and placebo doses were administered once daily for up to 14 days. Cohorts received repeat doses of GSK286 (225 or 650 mg; 13 participants) or placebo (four participants) in part B before the study was placed on hold due to reaching the stopping criterion, defined as clinically significant, non‐serious adverse events (AEs) that are considered to be at least possibly related to GSK286 in two or more participants on active treatment. Single GSK286 doses were well tolerated; all reported AEs were mild, apart from moderate AEs in two participants administered GSK286 1000 mg, and there were no serious AEs (SAEs). In part B (repeat dosing), three participants reported moderate AEs, one reported a severe AE, and there were no SAEs. However, four of six participants in the 650 mg repeat dose cohort discontinued treatment due to the AEs (at least one) of headache, photophobia, fatigue, nausea, and vomiting. There was high intraindividual variability in the pharmacokinetics of GSK286 in both parts of the study, and the effect of food in modulating this variability was unclear. The combination of unexpected pharmacokinetic variability and exposure‐related AEs led to termination of the study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, London, UK.
- GSK, Cambridge, UK.
- GSK, Stevenage, UK.
- Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- GSK, Tres Cantos, Spain.
ORCID-Profile: Emma Ilsley
Förderung
- GSK
- Innovative Medicines Initiative 2 Joint Undertaking (JU)
- GlaxoSmithKline foundation
Zitieren
APA
Ilsley, E., Banham-Hall, E., Chaychenko, T., Chinenyeze, K., Maher-Edwards, G., Muya, C., Rolfe, K., Sharma, R., Tiberi, S., & Barros-Aguirre, D. (2026). Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults. The Journal of Clinical Pharmacology, 66(5). https://doi.org/10.1002/jcph.70203
Vancouver
Ilsley E, Banham-Hall E, Chaychenko T, Chinenyeze K, Maher-Edwards G, Muya C, et al. Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults. The Journal of Clinical Pharmacology. 2026;66(5). doi:10.1002/jcph.70203
BibTeX
@article{Ilsley2026,
author = {Ilsley, Emma and Banham-Hall, Edward and Chaychenko, Tetyana and Chinenyeze, Katerina and Maher-Edwards, Gareth and Muya, Catherine and Rolfe, Katie and Sharma, Raman and Tiberi, Simon and Barros-Aguirre, David},
title = {Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {5},
doi = {10.1002/jcph.70203}
}
EUVIMED